These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 4007273)

  • 1. The control of biological medicinal products produced by recombinant DNA technology.
    Griffiths E
    Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality control of biologicals produced by r-DNA technology.
    Liu DT; Gates FT; Goldman ND
    Dev Biol Stand; 1985; 59():161-6. PubMed ID: 4007274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USDA licensing policy for biologicals produced by R-DNA.
    Espeseth DA; Shibley GP; Joseph PL; van Deusen RA; Whetstone CA
    Dev Biol Stand; 1985; 59():167-73. PubMed ID: 4007275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality control of biologicals produced by recombinant DNA techniques. WHO consultation.
    WHO Consultation
    Bull World Health Organ; 1983; 61(6):897-911. PubMed ID: 6609009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. License requirements for recombinant DNA veterinary biologics in U.S.A.
    La Salle B
    Dev Biol Stand; 1985; 59():181-4. PubMed ID: 4007277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of therapeutic goods produced by recombinant DNA technology.
    Breschkin A
    Dev Biol Stand; 1987; 67():207-11. PubMed ID: 3475226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensuring the consistency of rDNA-derived biologicals: the contribution of gene sequencing.
    Griffiths E
    Dev Biol Stand; 1994; 83():179-82. PubMed ID: 7883093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality assurance of products manufactured by recombinant DNA technology. Introduction and elements of a philosophy.
    van Noordwijk J
    Arzneimittelforschung; 1988 Jul; 38(7):943-7. PubMed ID: 3207439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.
    Wang M; Senger RS; Paredes C; Banik GG; Lin A; Papoutsakis ET
    Biotechnol Bioeng; 2009 Nov; 104(4):796-808. PubMed ID: 19591186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specifications and quality control of a yeast-derived hepatitis B vaccine.
    Peetermans JH
    Postgrad Med J; 1987; 63 Suppl 2():97-100. PubMed ID: 3317364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic stability and recombinant product consistency.
    Burstyn D; Copmann T; Dinowitz M; Garnick R; Losikoff A; Lubiniecki A; Wiebe M
    Biologicals; 1993 Jun; 21(2):147-9. PubMed ID: 8297595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of endotoxin removal from biological preparations: a review.
    Magalhães PO; Lopes AM; Mazzola PG; Rangel-Yagui C; Penna TC; Pessoa A
    J Pharm Pharm Sci; 2007; 10(3):388-404. PubMed ID: 17727802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory control of biological products in Latin America.
    Greenberg L
    Bull Pan Am Health Organ; 1975; 9(1):27-31. PubMed ID: 1148451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful development of recombinant DNA-derived pharmaceuticals.
    Werner RG; Pommer CH
    Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic stability and product consistency of rDNA derived biologicals.
    Lambert KJ
    Biologicals; 1993 Jun; 21(2):151. PubMed ID: 8297596
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.